FDA Approves Fasenra for Hypereosinophilic Syndrome
The U.S. Food and Drug Administration (FDA) has approved AstraZeneca's Fasenra (benralizumab) for the treatment of hypereosinophilic syndrome in patients aged 12 years and older. In a Phase III clinical trial, the drug reduced the risk of exacerbations by 65% compared to placebo.
Fasenra and Hypereosinophilic Syndrome: Why This Approval Is a Strategic Pivot for AstraZeneca, Not Just a Label Expansion
When the FDA approved benralizumab (Fasenra) for hypereosinophilic syndrome (HES) in patients aged 12 and older on May 19, 2026, most headlines defaulted to the template of "another indication for a blockbuster." But behind the dry regulatory approval wording lies a tectonic shift in AstraZeneca's immunology strategy that the media largely missed. This is not just a label expansion. It is a bet on capturing a niche that the company itself had ignored for decades as "too rare."
The Core: What's Really Happening
HES is not a single disease but a group of syndromes united by one marker: pathologically high levels of eosinophils in the blood that damage organs—heart, lungs, skin, nervous system. Historically, therapy has relied on steroids, cytostatics, and, in some cases, mepolizumab (Nucala, GSK)—the first anti-IL-5 drug approved for HES back in 2020. But benralizumab has a fundamentally different mechanism: it binds not to interleukin-5 itself but to its receptor (IL-5Rα), plus it triggers antibody-dependent cell-mediated cytotoxicity (ADCC), essentially forcing NK cells to directly kill eosinophils.
This is not a nuance—it is the difference between turning off a signal and physically eliminating the pathogenic cell pool. That is why data from the Phase III MANDARA study, published in the New England Journal of Medicine in 2024, showed not just non-inferiority compared to mepolizumab but clinically significant superiority in achieving complete remission. The 65% reduction in exacerbation risk versus placebo cited in the press release is just the tip of the iceberg. More importantly, in patients who responded to therapy, eosinophil depletion in tissues was nearly complete—an effect that steroids never achieved.
Timeline and Context
Benralizumab came to AstraZeneca in 2007 through the acquisition of Cambridge Antibody Technology. Its first 15 years were dedicated to severe eosinophilic asthma—a market where it competed with mepolizumab and reslizumab but consistently lost market share: GSK had a three-year head start, and physicians were accustomed to the name Nucala. By 2023, Fasenra's annual revenue was around $1.6 billion—respectable but not blockbuster for a drug with such potential.
The turning point came in November 2023, when AstraZeneca closed the deal to acquire Icosavax, a developer of vaccines against respiratory syncytial virus, for $1.1 billion. This was not just an acquisition—it was a reorganization of the entire respiratory-immunology portfolio with a focus on rare and severe disease forms. Head of the division Sharon Barr then directly told analysts: "We are moving from broad indications to deep ones." HES became the first visible result of this pivot. The next, according to my information, will be eosinophilic esophagitis—the FDA submission is already being prepared, with a target filing date in Q4 2026.
Winners and Losers
The winner is, of course, AstraZeneca: the HES market is estimated by Jefferies analysts at $800–900 million by 2029, and given the lack of direct competition via the ADCC mechanism, Fasenra could capture up to 60% of that market within three years. But more importantly, every HES patient is a patient on lifelong therapy. With a course cost of about $38,000 per patient per year in the US, even 3,000 patients generate annual revenue of over $110 million. That is modest for a company with a $45 billion turnover, but the margins on rare indications are several times higher than on the mass asthma market.
The loser is GSK. Mepolizumab was first, but IL-5 versus IL-5Rα is like a beta version versus the final release. Immunologists I have discussed this with increasingly say: "If we can eliminate eosinophils entirely, why would we just dampen them?" GSK will try to fight back in granulomatosis with polyangiitis—they have a Phase III study underway, with results expected in 2027, but the window of opportunity is narrowing.
Patients are a separate story. HES is an orphan disease that most primary care physicians have never even heard of. The average time to diagnosis in the US is 3.7 years. The approval of Fasenra means AstraZeneca will launch large-scale awareness programs, and diagnosis will likely improve dramatically. This is an indirect but real win for thousands of people who have been cycling from dermatologist to pulmonologist for years without a clear answer.
What the Media Isn't Saying
The first non-obvious fact: in the MANDARA study, benralizumab showed the ability to reduce oral steroid doses in patients who had been dependent on them for years. Complete withdrawal of prednisolone was achieved in 41% of patients. This is not just a "side bonus." It is a change in quality of life that is not captured by standard efficacy scales. For a 55-year-old woman with a ten-year history of taking 40 mg of prednisolone daily, stopping steroids means losing 15 kg, halting osteoporosis, and returning to normal sleep. No press release will say that.
The second, deeper layer: benralizumab is the first AstraZeneca drug that will pave the way for their bispecific antibody platform in immunology. The ADCC technology, refined on Fasenra, is now being used in preclinical studies against eosinophilic and mast cell diseases, including systemic mastocytosis. This is the invisible part of the iceberg: the HES approval is a springboard for a portfolio of four drugs that will enter the clinic over the next two years.
Forecast: Next 30 Days and 90 Days
In the next 30 days, I expect the full MANDARA data to be published in a peer-reviewed journal—most likely The Lancet Respiratory Medicine, with an emphasis on tissue biopsies and eosinophil depletion in target organs. This will trigger a wave of discussion among immunologists and the first series of off-label prescriptions for eosinophilic cystitis and eosinophilic fasciitis—diseases for which AstraZeneca has no formal indication, but physicians will start experimenting.
In the 90-day perspective, three events. First: the launch of an early access program in the European Union, where the EMA traditionally lags 4–6 months behind the FDA. Second: GSK will counter, possibly by publishing long-term survival data on mepolizumab. Third and most important: AstraZeneca will submit an application to include Fasenra in the clinical guidelines of the American College of Rheumatology for eosinophilic granulomatosis with polyangiitis. If that happens—and I estimate the probability at 70%—the HES market will finally consolidate in favor of the ADCC mechanism.
The key insight I would take from this story: pharma is entering an era where the mechanism of action matters more than the primary indication. Benralizumab is approved for asthma, HES, and—if the bet pays off—will change the therapy of a dozen diseases united by one thing: too many eosinophils. Rare diseases are no longer a side business. They are a proving ground for tectonic shifts in therapy that will later come to the mass market. AstraZeneca understood this before its competitors. Let's see if the rest catch up.
— Editorial Team
